Clinical Trials on Autosomal Dominant Tubulointerstitial Kidney Disease

Total 11740 results

Assistance Publique - Hôpitaux de Paris
Novartis

Completed

The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients (EVERKYSTE)

Autosomal Dominant Polycystic Kidney Disease

France
Galapagos NV

Terminated

A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

Belgium, Netherlands, Italy, Spain, Czechia, Germany, Poland
Palladio Biosciences

Completed

The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Tolvaptan Extension Study in Participants With ADPKD (TEMPO 4/4)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States, Australia, Belgium, Germany, Italy, Poland, Romania, United Kingdom, Argentina, Canada, France, Netherlands, Russian Federation
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]

Autosomal Dominant Polycystic Kidney Disease （ADPKD)

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (NOCTURNE)

Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]

Autosomal Dominant Polycystic Kidney Disease

Japan
Shanghai Changzheng Hospital

Unknown

Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

China
Yale University

Terminated

Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy

Autosomal Dominant Polycystic Kidney Disease

United States
Sanofi

Terminated

Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat (STAGED-PKD-EXT)

Congenital Cystic Kidney Disease

Germany, Spain, United States, Australia, Belgium, Japan, Korea, Republic of, Netherlands
NYU Langone Health

Completed

High Water Intake to Slow Progression of Polycystic Kidney Disease

Kidney, Polycystic, Autosomal Dominant

United States
University of Colorado, Denver
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

ADPKD

United States
Rigshospitalet, Denmark
Aarhus University Hospital

Completed

Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease

ADPKD

Denmark
Mayo Clinic

Completed

Pasireotide LAR in Severe Polycystic Liver Disease (SOM230)

Autosomal Dominant Polycystic Kidney Disease | Polycystic Liver Disease | Autosomal Dominant Polycystic Liver Disease | Somatostatin Analogs

United States
Otsuka Canada Pharmaceutical Inc.

Recruiting

Canadian Medical Assessment of JINARC™ Outcomes Registry (C-MAJOR)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Canada
University Hospital, Brest

Completed

Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD (GeneQuest)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

France
Medical University of Vienna

Unknown

Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease (RAP)

Polycystic Kidney, Type 1 Autosomal Dominant Disease | Polycystic Kidney, Type 2 Autosomal Dominant Disease

Austria
Mario Negri Institute for Pharmacological Research

Completed

Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency (ALADIN2)

Autosomal Dominant Polycystic Kidney Disease

Italy
The Rogosin Institute
Weill Medical College of Cornell University; New York Presbyterian Hospital

Withdrawn

Repository Study of Autosomal Dominant Polycystic Kidney Disease (Repository)

Autosomal Dominant Polycystic Kidney Disease

United States
Ministry of Health, Labour and Welfare, Japan

Unknown

Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)

Kidney, Polycystic, Autosomal Dominant

Japan
Mayo Clinic
Polycystic Kidney Disease Foundation

Completed

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study

Kidney, Polycystic, Autosomal Dominant

United States
Mei changlin

Unknown

Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control (RAFALE)

Hypertension | Autosomal Dominant Polycystic Kidney Disease

China
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease

Germany, Austria, France
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Chronic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease

Australia, Belgium, Italy, Spain, Sweden, United States, Canada, Netherlands, Czechia, Poland, Germany, Russian Federation, Hungary, Israel, Puerto Rico, Argentina, Denmark, South Africa, United Kingdom, Norway, France, Romania
Kyorin University
Ministry of Health, Labour and Welfare, Japan

Unknown

CCB Safety Study in Treatment of Hypertension of ADPKD

Kidney, Polycystic, Autosomal Dominant

Japan
Regulus Therapeutics Inc.

Recruiting

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant | Autosomal Dominant Polycystic Kidney Disease | ADPKD

United States
University of Southern California

Enrolling by invitation

Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD-SAT)

Autosomal Dominant Polycystic Kidney Disease

United States
Mario Negri Institute for Pharmacological Research

Recruiting

Outcome of ADPKD With Octreotide LAR (ADPKD648)

Autosomal Dominant Polycystic Kidney

Italy
Rege Nephro Co., Ltd.

Recruiting

Study of Tamibarotene in Patients With ADPKD

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Japan
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

United States
Weill Medical College of Cornell University
The Rogosin Institute

Enrolling by invitation

Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

United States
Taipei Medical University Shuang Ho Hospital
University of Southern California

Enrolling by invitation

Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease

Chronic Kidney Diseases | Autosomal Dominant Polycystic Kidney Disease

Taiwan
University of California, San Francisco

Recruiting

Genetic Testing in Autosomal Dominant Polycystic Kidney Disease

ADPKD

United States
Esther Meijer

Unknown

Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt (WATER)

Polycystic Kidney, Autosomal Dominant | Autosomal Dominant Polycystic Kidney | ADPKD

Netherlands
Universitair Ziekenhuis Brussel

Not yet recruiting

Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester? (ADKETONE)

ADPKD
University Hospital, Brest

Not yet recruiting

Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney Disease (COMPLIK)

Polycystic Kidney Diseases
Changlin Mei
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaborators

Completed

Using Preimplantation Genetic Diagnosis in Autosomal Dominant Polycystic Kidney Disease Patients: a Multicenter Clinical Trial (ESPERANCE)

Polycystic Kidney, Type 1 Autosomal Dominant Disease

China
Palladio Biosciences
Centessa Pharmaceuticals plc

Terminated

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ACTION)

Autosomal Dominant Polycystic Kidney | ADPKD

United States, Spain, Hungary, United Kingdom, Australia, Bulgaria, Poland, Turkey
Lisbet Brandi

Unknown

Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease (PoCKET)

Autosomal Dominant Polycystic Kidney

Denmark
Kyorin University

Completed

Efficacy Study of Water Drinking on PKD Progression. (ESWP)

Disease Progression | Autosomal Dominant Polycystic Kidney Disease

Japan
Radboud University Medical Center

Recruiting

Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts (ATLAS)

Autosomal Dominant Polycystic Kidney | Polycystic Liver Disease | Liver Cyst | Autosomal Dominant Polycystic Liver Disease

Netherlands
University Medical Center Groningen
Radboud University Medical Center

Recruiting

A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease (AGAINST-PLD)

Autosomal Dominant Polycystic Kidney | Polycystic Liver Disease

Netherlands
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield

Completed

The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant
University of Colorado, Denver

Active, not recruiting

Statin Therapy in Patients With Early Stage ADPKD

Autosomal Dominant Polycystic Kidney | ADPKD

United States
Kadmon, a Sanofi Company

Completed

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney | ADPKD

United States
University Hospital, Rouen

Not yet recruiting

Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease (ETERNAL-PKD)

Kidney Diseases
Genzyme, a Sanofi Company

Terminated

A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients (STAGED-PKD)

Polycystic Kidney, Autosomal Dominant

Belgium, Germany, Czechia, United States, Italy, Poland, Argentina, Australia, Austria, Canada, China, Denmark, France, Israel, Japan, Korea, Republic of, Netherlands, Portugal, Romania, Spain, Taiwan, Turkey, United Kingdom
Erasmus Medical Center

Recruiting

Treatment of Vascular Stiffness in ADPKD (TRAMPOLINE)

Autosomal Dominant Polycystic Kidney

Netherlands
University of Erlangen-Nürnberg Medical School

Recruiting

Renal Denervation in ADPKD- RDN-ADPKD Study (RDN-ADPKD)

Autosomal Dominant Polycystic Kidney Disease | Uncontrolled Hypertension | Renal Denervation

Germany
Genzyme, a Sanofi Company

Completed

Effect of Venglustat in Patients With Renal Impairment

Healthy Volunteers | Polycystic Kidney, Autosomal Dominant

United States

Clinical Trials on Autosomal Dominant Tubulointerstitial Kidney Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations